Emerging drugs for partial onset seizures

Bibliography

• Engel J Jr. Seizures and Epilepsy. FA Davis. Philadelphia; 1989
   Google Scholar
• Banerjee PN, Filippi D, Allen Hauser W. The descriptive epidemiology of epilepsy-a review. Epilepsy Res 2009;85(1):31-45
   PubMed Web of Science ®Google Scholar
• Birbeck G, Chomba E, Atadzhanov M, The social and economic impact of epilepsy in Zambia: a cross-sectional study. Lancet Neurol 2007;6(1):39-44
   PubMed Web of Science ®Google Scholar
• Kelvin EA, Hesdorffer DC, Bagiella E, Prevalence of self-reported epilepsy in a multiracial and multiethnic community in New York City. Epilepsy Res 2007;77(2-3):141-50
   PubMed Web of Science ®Google Scholar
• Noronha AL, Borges MA, Marques LH, Prevalence and pattern of epilepsy treatment in different socioeconomic classes in Brazil. Epilepsia 2007;48(5):880-5
   PubMed Web of Science ®Google Scholar
• Hsieh LP, Huang CY. Prevalence of treated epilepsy in western medicine among the adult population in Taiwan: a study conducted using antiepileptic drug prescription data. Epilepsy Res 2008;80(2-3):114-8
   PubMed Web of Science ®Google Scholar
• Pugliatti M, Beghi E, Forsgren L, Estimating the cost of epilepsy in Europe: a review with economic modeling. Epilepsia 2007;48(12):2224-33
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Reese JP, Dodel R, Hamer HM. Cost of epilepsy: a systematic review. Pharmacoeconomics 2008;26(6):463-76
   PubMed Web of Science ®Google Scholar
• Jacoby A, Gorry J, Baker GA. Employers' attitudes to employment of people with epilepsy: still the same old story? Epilepsia 2005;46(12):1978-87
   PubMed Web of Science ®Google Scholar
• Parfene C, Stewart TL, King TZ. Epilepsy stigma and stigma by association in the workplace. Epilepsy Behav 2009;15(4):461-6
   PubMed Web of Science ®Google Scholar
• Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics 2007;4(1):18-61
   PubMed Web of Science ®Google Scholar
• Birbeck GL, Hays RD, Cui X, Vickrey BG. Seizure reduction and quality of life improvements in people with epilepsy. Epilepsia 2002;43(5):535-8
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001;42(10):1255-60
   PubMed Web of Science ®Google Scholar
• Callaghan BC, Anand K, Hesdorffer D, Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 2007;62(4):382-9
   PubMed Web of Science ®Google Scholar
• Luciano AL, Shorvon SD. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 2007;62(4):375-81
   PubMed Web of Science ®Google Scholar
• Gazzola DM, Balcer LJ, French JA. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia 2007;48(7):1303-7
   PubMed Web of Science ®Google Scholar
• Jung MJ, Lippert B, Metcalf BW, gamma-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neurochem 1977;29(5):797-802
   PubMed Web of Science ®Google Scholar
• Schechter PJ, Hanke NF, Grove J, Biochemical and clinical effects of gamma-vinyl GABA in patients with epilepsy. Neurology 1984;34(2):182-6
   PubMed Web of Science ®Google Scholar
• Horton RW, Collins JF, Anlezark GM, Meldrum BS. Convulsant and anticonvulsant actions in DBA/2 mice of compounds blocking the reuptake of GABA. Eur J Pharmacol 1979;59(1-2):75-83
   PubMed Web of Science ®Google Scholar
• Schachter SC. A review of the antiepileptic drug tiagabine. Clin Neuropharmacol 1999;22(6):312-7
   PubMed Web of Science ®Google Scholar
• Panayiotopoulos CP. The epilepsies: seizures, syndromes and management. Bladon Medical Publishing, Oxfordshire; 2005
   Google Scholar
• Knoester P, Deckers C, van der Vaart R, Volume and market share of anti-epileptic drugs in The Netherlands: impact of new drugs. Pharm World Sci 2005;27(2):129-34
   PubMed Web of Science ®Google Scholar
• Available from: http://www.wikinvest.com/wiki/Antiepileptic_Drug_Market
   Google Scholar
• Loscher W. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res 2002;50(1-2):105-23
   PubMed Web of Science ®Google Scholar
• Dichter MA. Basic mechanisms of epilepsy: targets for therapeutic intervention. Epilepsia 1997;38(Suppl 9):S2-6
   PubMedGoogle Scholar
• Dichter MA. Emerging concepts in the pathogenesis of epilepsy and epileptogenesis. Arch Neurol 2009;66(4):443-7
   PubMed Web of Science ®Google Scholar
• Najm IM, Janigro D, Babb TL. Mechanisms of epileptogenesis and experimental models of seizures. In: Wyllie E, editor, The treatment of epilepsy: principles and practice. 3rd edition. Lippincott Williams & Wilkins, Philadelphia; 2001. p. 33-44.
   Google Scholar
• Available from: http://informa.citeline.com
   Google Scholar
• Arroyo S. Rufinamide. Neurotherapeutics 2007;4(1):155-62
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res 2009;83(1):1-43
   PubMed Web of Science ®Google Scholar
• Fuseau E, Critchley D, Perdomo C, Arroyo S. Population pharmacokinetic drug- drug interaction analyses of rufinamide studies in patients with epilepsy [abstract]. Epilepsia 2005;46(Suppl 8):210-1
   Google Scholar
• Glauser T, Kluger G, Sachdeo R, Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008;70(21):1950-8
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Rosenfeld WE, Vazquez B, Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 2009;50(8):1899-909
   PubMed Web of Science ®Google Scholar
• Beydoun A, D'Souza J, Hebert D, Doty P. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother 2009;9(1):33-42
   PubMed Web of Science ®Google Scholar
• Johannessen Landmark C, Johannessen SI. Pharmacological management of epilepsy: recent advances and future prospects. Drugs 2008;68(14):1925-39
   PubMed Web of Science ®Google Scholar
• Almeida L, Soares-da-Silva P. Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics 2007;4(1):88-96
   PubMed Web of Science ®Google Scholar
• Bonifacio MJ, Sheridan RD, Parada A, Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia 2001;42(5):600-8
   PubMed Web of Science ®Google Scholar
• Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep 2009;61(2):197-216
   PubMed Web of Science ®Google Scholar
• Elger C, Bialer M, Cramer JA, Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 2007;48(3):497-504
   PubMed Web of Science ®Google Scholar
• Elger C, Halasz P, Maia J, Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009;50(3):454-63
   PubMed Web of Science ®Google Scholar
• Gil-Nagel A, Lopes-Lima J, Almeida L, Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand 2009;120(5):281-7
   PubMed Web of Science ®Google Scholar
• Brown DA, Adams PR. Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone. Nature 1980;283(5748):673-6
   PubMed Web of Science ®Google Scholar
• Rogawski MA, Bazil CW. New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep 2008;8(4):345-52
   PubMed Web of Science ®Google Scholar
• Rundfeldt C, Netzer R. Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung 2000;50(12):1063-70
   PubMed Web of Science ®Google Scholar
• Tober C, Rostock A, Rundfeldt C, Bartsch R. D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol 1996;303(3):163-9
   PubMed Web of Science ®Google Scholar
• Ferron GM, Paul J, Fruncillo R, Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol 2002;42(2):175-82
   PubMed Web of Science ®Google Scholar
• Hempel R, Schupke H, McNeilly PJ, Metabolism of retigabine (D-23129), a novel anticonvulsant. Drug Metab Dispos 1999;27(5):613-22
   PubMed Web of Science ®Google Scholar
• Porter RJ, Nohria V, Rundfeldt C. Retigabine. Neurotherapeutics 2007;4(1):149-54
   PubMed Web of Science ®Google Scholar
• French JA, Mansbach H. 1200 mg/day retigabine as adjunctive therapy in adults with refractory partial-onset seizures. Epilepsia 2008;49(Suppl 7):112-3
   Google Scholar
• Brodie M, Mansbach H. Retigabine 600 or 900 mg/day as adjunctive therapy in adults with partial-onset seizures [abstract]. Epilepsia 2008;49(Suppl 7):110
   Google Scholar
• Beydoun A, Nasreddine W, Atweh S. Efficacy and tolerability of pregabalin in partial epilepsy. Expert Rev Neurother 2008;8(7):1013-24
   PubMedGoogle Scholar
• Yang XF, Weisenfeld A, Rothman SM. Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission. Epilepsia 2007;48(10):1861-9
   PubMed Web of Science ®Google Scholar
• Rogawski MA. Brivaracetam: a rational drug discovery success story. Br J Pharmacol 2008;154(8):1555-7
   PubMed Web of Science ®Google Scholar
• Rolan P, Sargentini-Maier ML, Pigeolet E, Stockis A. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol 2008;66(1):71-5
   PubMed Web of Science ®Google Scholar
• Sargentini-Maier ML, Espie P, Coquette A, Stockis A. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos 2008;36(1):36-45
   PubMed Web of Science ®Google Scholar
• von Rosenstiel P. Brivaracetam (UCB 34714). Neurotherapeutics 2007;4(1):84-7
   PubMed Web of Science ®Google Scholar
• Matagne A, Margineanu DG, Kenda B, Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol 2008;154(8):1662-71
   PubMed Web of Science ®Google Scholar
• Otoul C, von Rosenstiel P, Stockis A. Evaluation of the pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with partial-onset seizures [abstract]. Epilepsia 2007;48(Suppl 6):334
   Google Scholar
• Kasteleijn-Nolst Trenite DG, Genton P, Parain D, Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology 2007;69(10):1027-34
   PubMed Web of Science ®Google Scholar
• French JA, Brodsky A, von Rosenstiel P. Efficacy and tolerability of 5, 20 and 50 mg/day brivaracetam (UCB 34714) as adjunctive treatment in adults with refractory partial-onset seizures [abstract]. Epilepsia 2007;48(Suppl 6):400
   PubMed Web of Science ®Google Scholar
• Van Paesschen W, Brodsky A. Efficacy and tolerability of 50 and 150 mg/day brivaracetam (UCB 34714) as adjunctive treatment in adults with refractory partial-onset epilepsy [abstract]. Epilepsia 2007;48(Suppl 6):329
   Google Scholar
• Nohria V, Giller E. Ganaxolone. Neurotherapeutics 2007;4(1):102-5
   PubMed Web of Science ®Google Scholar
• Monaghan EP, Navalta LA, Shum L, Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia 1997;38(9):1026-31
   PubMed Web of Science ®Google Scholar
• Laxer K, Blum D, Abou-Khalil BW, Assessment of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design. Ganaxolone Presurgical Study Group. Epilepsia 2000;41(9):1187-94
   PubMed Web of Science ®Google Scholar
• Chiron C. Stiripentol. Neurotherapeutics 2007;4(1):123-5
   PubMed Web of Science ®Google Scholar
• Poisson M, Huguet F, Savattier A, A new type of anticonvulsant, stiripentol. Pharmacological profile and neurochemical study. Arzneimittelforschung 1984;34(2):199-204
   PubMed Web of Science ®Google Scholar
• Chiron C, Tonnelier S, Rey E, Stiripentol in childhood partial epilepsy: randomized placebo-controlled trial with enrichment and withdrawal design. J Child Neurol 2006;21(6):496-502
   PubMed Web of Science ®Google Scholar
• Chiron C, Marchand MC, Tran A, Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000;356(9242):1638-42
   PubMed Web of Science ®Google Scholar
• Novak GP, Kelley M, Zannikos P, Klein B. Carisbamate (RWJ-333369). Neurotherapeutics 2007;4(1):106-9
   PubMed Web of Science ®Google Scholar
• Mannens GS, Hendrickx J, Janssen CG, The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-) in humans. Drug Metab Dispos 2007;35(4):554-65
   PubMed Web of Science ®Google Scholar
• Yao C, Doose DR, Novak G, Bialer M. Pharmacokinetics of the new antiepileptic and CNS drug RWJ-333369 following single and multiple dosing to humans. Epilepsia 2006;47(11):1822-9
   PubMed Web of Science ®Google Scholar
• Chien S, Bialer M, Solanki B, Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults. Epilepsia 2006;47(11):1830-40
   PubMed Web of Science ®Google Scholar
• Faught E, Holmes GL, Rosenfeld WE, Randomized, controlled, dose-ranging trial of carisbamate for partial-onset seizures. Neurology 2008;71(20):1586-93
   PubMed Web of Science ®Google Scholar
• Sperling MR, Greenspan A, Cramer JA, Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo-controlled trials. Epilepsia 2010;51(3):333-43
   PubMed Web of Science ®Google Scholar
• Remy S, Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 2006;129(Pt 1):18-35
   PubMed Web of Science ®Google Scholar